Lantern Pharma Inc Stock Price, News & Analysis

Lantern Pharma (LTRN) announced a strategic collaboration with Deep Lens, aimed at accelerating patient enrollment for its Phase 2 clinical trial of LP-300 in never-smokers with non-small cell lung cancer (NSCLC). This partnership integrates Deep Lens' VIPER AI platform, enhancing patient matching to clinical trials. Lantern's RADR® AI technology will help identify biomarker signatures for effective oncological therapies. The goal is to streamline the complex drug development process, reduce costs, and improve access to treatments for cancer patients, particularly in the underserved demographic of never-smokers.

Lantern Pharma (NASDAQ: LTRN) announced that President & CEO Panna Sharma will present at the Benzinga Healthcare Small Cap Conference virtually from September 29-30, 2021. Sharma's presentation is scheduled for September 29 at 11:55 AM ET, with one-on-one meetings available throughout the event. Lantern Pharma is focused on oncology drug development, utilizing its proprietary RADR® A.I. platform to identify patients likely to benefit from their genomically targeted therapeutics.

Lantern Pharma (NASDAQ: LTRN) announced participation in two virtual investor conferences in September 2021. Panna Sharma, President & CEO, will host one-on-one meetings at the Colliers Institutional Investor Conference on September 9-10. Additionally, he will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, with a presentation available on-demand starting September 13 at 7:00 AM ET. Lantern Pharma leverages its RADR® A.I. platform to discover targeted therapies for oncology, complimented by four drug candidates in development.

Lantern Pharma (NASDAQ: LTRN) announced key additions to its leadership team to strengthen its clinical and manufacturing operations. Dr. Harry Kochat takes on the role of Senior Director of Chemistry, Manufacturing and Controls, bringing over 30 years of experience in drug development and quality control. Darlene Bunpian joins as Clinical Trial Project Manager, overseeing the planned Phase 2 trial of LP-300 in Non-Small Cell Lung Cancer. The company aims to advance its oncology drug development utilizing its RADR® A.I. platform, while the new appointments are expected to enhance operational capabilities.

Lantern Pharma (LTRN) announced positive preclinical results for its drug candidate LP-184 against glioblastoma (GBM). The study showed LP-184 inhibits tumor growth by over 106% and extends survival in mice by 27% compared to controls. Conducted with Johns Hopkins, the findings support LP-184's potential in treating GBM, particularly in patients unresponsive to standard therapies. Lantern plans to refine dosing regimens and strengthen its FDA orphan drug application. This signifies a step towards addressing critical gaps in GBM treatment, benefiting patients with varying tumor profiles.

Lantern Pharma (LTRN) announced that its abstract, titled 'LP-184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects', has been accepted for presentation at the AACR Virtual Special Conference on Pancreatic Cancer on September 29-30, 2021. The abstract highlights LP-184's promising efficacy in pancreatic cancer models, especially with DNA repair deficiencies. The drug has received Orphan Drug Designation from the FDA for pancreatic cancer treatment.

Lantern Pharma (LTRN) announced that the FDA has granted Orphan Drug Designation for its drug candidate LP-184, aimed at treating pancreatic cancer. This designation will provide seven years of market exclusivity, tax credits, and other benefits, enhancing the potential for LP-184's development. LP-184 has shown significant tumor shrinkage in preclinical models, highlighting its promise. The drug targets specific pancreatic cancer patients with certain biomarkers, potentially improving treatment outcomes in a cancer with a poor survival rate of 7.9% over five years.

Lantern Pharma (LTRN) reported its Q2 2021 financial results, highlighting significant advancements in its cancer therapy pipeline. The company aims to expedite drug development using its RADR® A.I. platform, with promising data from its LP-184 program targeting pancreatic cancer and other malignancies. Cash reserves surged to $79.6 million, aided by a $69 million public offering. However, R&D expenses increased to $1.16 million, contributing to a net loss of $2.32 million, or $0.21 per share. Upcoming milestones include clinical trials for LP-300 and data from collaborations with leading cancer research institutions.

Lantern Pharma (LTRN) announced an Asset Purchase Agreement to reacquire global development and commercialization rights for Irofulven (LP-100) from Allarity. This transaction also grants Lantern exclusive licensing to Allarity's companion diagnostic. The company is set to assume full control over LP-100's clinical development, which targets prostate and bladder cancer patients with ERCC2/3 gene mutations. Initial Phase 2 trial data showed a median overall survival of 12.5 months for treated patients. Lantern plans to expand its trials and aims for potential regulatory approvals in the US and EU.